NAB2-STAT6 Fusion Proteins Drive Nuclear Condensate Formation and Transcriptional Reprogramming in Solitary Fibrous Tumors

Authors:
  • JMJose L. Mondaza-Hernandez
    Jose L. Mondaza-Hernandez
  • GPGauthami Pulivendala
    Gauthami Pulivendala
  • FEFardous Elsenduny
    Fardous Elsenduny
  • FBFelipe Beckedorff
    Felipe Beckedorff
  • GLGuilherme M. Lavezzo
    Guilherme M. Lavezzo
  • FAFarhan Vahdat Azad
    Farhan Vahdat Azad
  • ZZZikun Zhou
    Zikun Zhou
  • JWJeremy Warren
    Jeremy Warren
  • PTPaulina I. Trevino
    Paulina I. Trevino
  • CMClark A. Meyer
    Clark A. Meyer
  • DLDavid Lombard
    David Lombard

Abstract
Solitary fibrous tumor (SFT) is a rare and aggressive sarcoma driven by NAB2-STAT6 gene fusions, yet effective targeted therapies remain unavailable. Here, we report that the NAB2ex4-STAT6ex2 fusion variant forms nuclear condensates via liquid-liquid phase separation (LLPS) in engineered fibroblast models and primary SFT cells. These condensates co-localize with BRD4S and EGR1, key transcriptional regulators, and are functionally active, driving widespread transcriptional reprogramming. Treatment with Mithramycin A, a compound that disrupts EGR1-DNA interactions, dissolves NAB2-STAT6 condensates and reverses their aberrant gene expression and chromatin binding signatures. Our findings uncover a previously unrecognized role for NAB2-STAT6 in condensate-mediated oncogenic signaling and provide a mechanistic rationale for condensate-targeted therapy in SFT.
All Related Versions
Funding Information
  • the Horowitz Solitary Fibrous Tumor initiative
  • the Miami VA Healthcare System GRECC
  • National Institute of Health Carlos III